The CheckMate 77T trial enrolled patients with resectable NSCLC, including those diagnosed with the more advanced Stage III N2 nodal disease. The investigation focused on the perioperative use of nivolumab combined with chemotherapy, followed by surgical resection and adjuvant therapy, comparing these outcomes against a control group receiving placebo plus chemotherapy. Critically, beyond traditional endpoints such as event-free and overall survival, this study incorporated robust patient-reported outcome (PRO) measures to meticulously evaluate the impact of treatment on symptom burden and overall quality of life.

The HRQoL assessment employed validated instruments including the NSCLC-Symptom Assessment Questionnaire (NSCLC-SAQ) and the EQ-5D-3L visual analogue scale (VAS), both internationally recognized tools for capturing subjective patient well-being and symptom severity. High completion rates exceeding 90% were achieved across most evaluation time points, underscoring the reliability and consistency of the data collected. These metrics allowed researchers to discern subtle differences in symptom trajectories and quality of life alterations throughout the treatment continuum, from the neoadjuvant phase through postoperative recovery and adjuvant therapy.

According to Dr. Jonathan Spicer of the McGill University Health Centre, a leading investigator in the trial, maintaining a patient’s quality of life through often-toxic cancer therapies remains an indispensable objective alongside prolonging survival. “Our data reveal that perioperative nivolumab sustains health-related quality of life without introducing significant additional symptom burden, a crucial consideration for patients facing complex multimodal treatment,” he explained during the WCLC presentation. The results thus reinforce nivolumab’s dual role in enhancing disease control while concurrently supporting patient well-being.

Particularly notable were findings from the subset of patients with Stage III N2 disease, a cohort historically associated with poorer prognoses and increased treatment-related morbidity. In this high-risk group, nivolumab appeared to halve the risk of clinically meaningful deterioration in HRQoL compared to placebo. Specifically, hazard ratios for deterioration were 0.50 (95% confidence interval [CI]: 0.28–0.88) on the NSCLC-SAQ and 0.47 (95% CI: 0.27–0.82) on the EQ-5D-3L VAS. These statistically significant outcomes suggest that nivolumab’s immunomodulatory effects may mitigate symptom progression or treatment toxicity more effectively than chemotherapy alone in this vulnerable population.

Moreover, the quality of life benefits were sustained across different surgical modalities, including patients who underwent single lobectomy or complete resection. This aspect is clinically relevant, as the extent of surgical intervention can profoundly influence postoperative recovery trajectories and long-term functional status. The data indicate that administering nivolumab pre- and post-operatively does not compromise surgical outcomes or exacerbate recovery-associated symptoms, thereby affirming its safety profile in combination with standard surgical treatment.

The trial’s comprehensive approach to evaluating PROs marks a critical evolution in oncology research, shifting focus beyond traditional clinician-reported endpoints to embrace the patient’s perspective. This patient-centric paradigm is crucial in lung cancer care, where treatment regimens are often complex, and balancing efficacy with tolerability can markedly influence adherence and overall treatment success. By integrating detailed HRQoL data, CheckMate 77T sets a precedent for future trials aiming to align therapeutic advances with real-world patient experiences.

The broader implications of these findings extend to clinical decision-making, as oncologists grapple with optimizing perioperative strategies in resectable NSCLC. The confirmation that nivolumab does not detrimentally impact quality of life provides oncologists with robust evidence to advocate for its inclusion in treatment protocols, especially for patients at high risk of recurrence. This supports the evolving standard of care paradigm that increasingly incorporates immunotherapy as a critical adjunct to surgery and chemotherapy.

The IASLC, the global authority hosting the WCLC, continues to spearhead efforts in consolidating scientific breakthroughs and disseminating best practices in thoracic oncology. Its mission to foster multidisciplinary collaboration among lung cancer specialists underscores the importance of sharing real-world data and emerging clinical insights, such as those from CheckMate 77T, to improve patient outcomes worldwide. Lung cancer remains the leading cause of cancer-related mortality globally, and advancements that simultaneously extend survival and maintain quality of life are pivotal.

The CheckMate 77T trial findings also exemplify the rapid advancement in immuno-oncology and precision medicine within lung cancer. Nivolumab’s mechanism as a PD-1 checkpoint inhibitor unleashes the immune system’s ability to recognize and eliminate tumor cells, a strategy that has transformed the therapeutic landscape for many malignancies. Its application in the perioperative setting represents a novel approach to eradicating micrometastatic disease early in the disease course, thereby potentially improving long-term disease control.

Critical to the interpretation of these outcomes is recognition of the trial’s rigorous design, including randomization and placebo control, which strengthen the validity of the HRQoL findings. The consistency of patient responses across diverse global populations enhances the generalizability of the results, allowing clinicians to extrapolate these benefits to varied demographic cohorts encountered in routine practice.

In conclusion, the CheckMate 77T trial substantiates perioperative nivolumab as a transformative therapeutic modality in resectable NSCLC, delivering meaningful extensions in event-free survival while safeguarding patient-reported quality of life. These dual benefits are especially pronounced in patients with Stage III N2 disease, a subgroup with historically limited treatment options and high unmet clinical need. As these findings permeate the thoracic oncology community, they set the stage for revised clinical guidelines and herald a new standard where survival gains are no longer achieved at the expense of quality of life.

Subject of Research: Perioperative use of nivolumab in resectable non-small cell lung cancer (NSCLC) and its impact on health-related quality of life

Article Title: Phase 3 CheckMate 77T Trial Confirms Perioperative Nivolumab Preserves Quality of Life in Resectable NSCLC, Including Stage III N2 Patients

News Publication Date: September 6, 2025

Web References:
https://www.iaslc.org — International Association for the Study of Lung Cancer
https://www.wclc2025.org — World Conference on Lung Cancer 2025

Keywords: Lung cancer, non-small cell lung cancer, NSCLC, perioperative nivolumab, immunotherapy, CheckMate 77T, quality of life, HRQoL, patient-reported outcomes, PD-1 inhibitor, Stage III N2, surgical oncology

The research was conducted retrospectively on a cohort of 171 patients diagnosed with advanced NSCLC who underwent combined immune checkpoint inhibitor (ICI) therapy and chemotherapy. The investigators meticulously gathered clinical data alongside peripheral blood inflammatory markers to construct predictive models that could serve as reliable biomarkers for therapy efficacy and prognosis. Their focus centered on the systemic inflammatory response, particularly examining the NLR, fibrinogen levels, and other hematologic indices as potential indicators of therapeutic success or failure.

Among patients receiving first-line ICI plus chemotherapy, the study identified a critical threshold for pre-treatment NLR: values exceeding 3.3 correlated strongly with diminished progression-free survival (PFS). Elevated fibrinogen levels (greater than 3.196 g/L) similarly signaled poorer treatment outcomes. These findings underscore the interplay between systemic inflammation and cancer progression, highlighting how an imbalanced immune milieu marked by neutrophilia relative to lymphocytes may foster an environment conducive to tumor resistance and progression.

Crucially, the researchers developed a composite prognostic score combining NLR and fibrinogen—termed the NLR-Fib (NF) score—which demonstrated superior predictive accuracy compared to programmed cell death ligand 1 (PD-L1) expression assessed from tumor biopsies. PD-L1 has traditionally been utilized as a biomarker to select candidates for immunotherapy, but its variability and limitations have prompted the search for alternative or complementary measures. The NF score, derived from routine blood tests, offers a noninvasive, cost-effective, and reproducible tool for risk stratification in clinical practice.

The study also delved into a subset of NSCLC patients harboring targetable oncogenic driver mutations and treated with ICI plus chemotherapy beyond the first line. Here, a slightly higher NLR threshold of 3.53 was indicative of worse therapeutic responses and independently predicted both progression-free and overall survival (OS). Interestingly, prior duration of tyrosine kinase inhibitor (TKI) therapy exceeding 12 months emerged as an independent favorable prognostic factor for overall survival. This observation suggests that sustained disease control with targeted agents before immunotherapy may prime tumors for better responsiveness.

Further complexity was added by the identification of other factors influencing outcomes in this patient group. Secondary mutations such as the epidermal growth factor receptor (EGFR) T790M variant were associated with reduced PFS, as were a platelet-to-lymphocyte ratio (PLR) above 196.81 and hypoalbuminemia with albumin levels below 40.25 g/L. These markers collectively reflect the tumor’s evolving biology and systemic host factors that potentially modulate therapeutic efficacy.

Building on these insights, the authors formulated another prognostic metric termed the NLR-TKI-PFS (NTP) score, incorporating NLR levels and prior TKI progression-free survival time. This score stratified patients into three distinct risk categories — favorable, intermediate, and poor — correlating with median OS of 21, 12, and 5.3 months, respectively. Such a tool holds promise for guiding personalized treatment decisions and counseling patients regarding their prognosis in advanced disease stages.

The impact of this study extends beyond its immediate clinical findings. It challenges the current reliance on tissue-based biomarkers like PD-L1, which are often hampered by tumor heterogeneity, sampling bias, and dynamic expression changes. By contrast, systemic inflammation markers measured through blood tests provide a holistic snapshot of the host-tumor interaction and can be serially monitored to adapt treatment strategies.

Moreover, the accessibility and cost-effectiveness of blood-based biomarkers ensure the applicability of these prognostic scores even in resource-limited settings. As immunotherapy revolutionizes oncology care worldwide, such practical tools are imperative to optimize patient outcomes, avoid unnecessary toxicities, and contain healthcare costs.

The biological rationale underpinning the prognostic significance of NLR and fibrinogen is grounded in their roles in cancer pathophysiology. Neutrophils promote tumor progression by secreting pro-angiogenic factors and immunosuppressive cytokines, while lymphocytes, particularly cytotoxic T cells, are critical for anti-tumor immunity. A high NLR thus reflects a state of immune dysregulation favoring tumor escape. Elevated fibrinogen, a key coagulation factor, is implicated in tumor metastasis and inflammatory processes, further aggravating disease progression.

Beyond the statistical associations, this study advocates for integrating inflammatory markers into comprehensive clinical algorithms. Such integration may improve patient selection for immunotherapy and inform the timing of therapeutic interventions, combining or sequencing agents to overcome resistance mechanisms.

Future directions informed by this work include prospective validation trials to confirm the robustness of the NF and NTP scores across diverse populations and treatment regimens. Additionally, research into mechanistic links between inflammation and immunotherapy response could unveil novel therapeutic targets, potentially allowing modulation of the inflammatory milieu to enhance treatment efficacy.

Importantly, this research touches upon the personalized medicine paradigm, where nuanced patient stratification transcends conventional histological and genetic classifications. By incorporating systemic factors reflective of the host-tumor ecosystem, clinicians can better predict clinical trajectories and tailor interventions accordingly.

In summary, the study published in BMC Cancer heralds a promising advance in the prognostication of advanced NSCLC patients receiving ICI plus chemotherapy. Through innovative use of simple hematologic parameters, it provides a window into the complex interplay between cancer, host immunity, and treatment response. These insights bear the potential to refine therapeutic precision, improve survival outcomes, and ultimately transform patient care paradigms in oncology.

Subject of Research: Prognostic biomarkers in advanced non-small cell lung cancer treated with immunotherapy plus chemotherapy.

Article Title: Neutrophil-to-lymphocyte ratio-based prognostic score can predict outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy plus chemotherapy.

Article References:
Liao, S., Sun, H., Lu, H. et al. Neutrophil-to-lymphocyte ratio-based prognostic score can predict outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy plus chemotherapy.
BMC Cancer 25, 697 (2025). https://doi.org/10.1186/s12885-025-13811-y

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-13811-y